在STAMPEDE 试验中随机分配接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量...
In this largest randomized trial in prostate cancer conducted to date, a total of 10 different study arms are planned to enroll 8,100 patients with an allocation ratio of 2 patients into the control arm (arm A) to 1 patient into one of the 9 experimental arms, of which 6 arms are no...
Rush HL, MurphyL, Morgans AK, et al. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. J Clin Oncol. 2021 Nov 10;JCO2100728. doi: 10.1200/JCO.21.00728.
在STAMPEDE 试验中随机分配接受多西他赛或阿比特龙治疗的前列腺癌男性的生活质量 Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志( JCO )》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. 摘要 《临床肿瘤学杂志(JCO)》在2022年发表了一篇关于多西他赛或阿比特龙治疗的前列腺癌男性的生活质量的研究。由于多西他赛或醋酸阿比特龙联合泼尼松或泼尼松龙(AAP)在局部晚期或转移性激素...
[1]annoh L. Rush, et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. 2020 ASCO-GU. Oral presentation #GU20 [2]Sydes M, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly...
[4]mes ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. ...
which was really exciting but a little mind-blowing. What we heard discussed, though, was that STAMPEDE was predominantly de novo metastatic disease, so most of these patients came into the trial not having had treatment for their primary prostate cancer. In that population, there seemed to be...
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled Trial Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi‐arm, multistage randomized controlled trial ...
STAMPEDE is a multi-arm multi-stage randomised controlled trial protocol, recruiting men with locally advanced or metastatic prostate cancer who are commencing long-term androgen deprivation therapy. Opening to recruitment with five research questions in 2005 and adding in a further five questions over...